

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock code: 0460)

VOLUNTARY ANNOUNCEMENT

FONDAPARINUX SODIUM INJECTION OBTAINED MANUFACTURE APPROVAL

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the anticoagulant drug “fondaparinux sodium injection” (the “**Product**”) (strength: 0.5ml: 2.5mg) developed by the Group has been granted with drug registration approval for manufacture by the National Medical Products Administration of the People’s Republic of China and is deemed to have passed the quality and efficacy consistency evaluation of generic drugs.

Fondaparinux sodium injection is indicated for the prevention of venous thromboembolic events in patients undergoing major orthopedic surgeries of the lower limbs, such as hip fracture surgery, major knee surgery or hip replacement surgery; for the treatment of patients with unstable angina or non-ST-segment elevation myocardial infarction (UA/NSTEMI) receiving emergency (<120 mins) percutaneous coronary intervention (PCI) without indications; for the treatment of patients with ST-segment elevation myocardial infarction who are using thrombolytics or who initially did not receive other forms of reperfusion therapy. Fondaparinux sodium injection is included in the 2021 edition of the National Reimbursement Drug List (Class B). The obtaining of drug registration approval in relation to the Product is expected to be beneficial to the future market sales and market competition of the Product, as well as further benefit the majority of patients and make positive impact on the operation results of the Group.

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, the Group is an international pharmaceutical and medical aesthetics company led by innovation, with an independent and leading independent production and research and development technology platform, a rich global product pipeline and a mature and excellent sales system. Adhering to the overall strategic goal for the full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses, the Group endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 21 December 2021

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.